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ABSTRACT
MiRNA expression abnormalities in adenocarcinoma arising from pancreatic 
ductal system (PDAC) and Vater’s papilla (PVAC) could be associated with distinctive 
pathologic features and clinical cancer behaviours. Our previous miRNA expression 
profiling data on PDAC (n=9) and PVAC (n=4) were revaluated to define differences/
similarities in miRNA expression patterns. Afterwards, in order to uncover target 
genes and core signalling pathways regulated by specific miRNAs in these two 
tumour entities, miRNA interaction networks were wired for each tumour entity, and 
experimentally validated target genes underwent pathways enrichment analysis.
One hundred and one miRNAs were altered, mainly over-expressed, in PDAC 
samples. Twenty-six miRNAs were deregulated in PVAC samples, where more miRNAs 
were down-expressed in tumours compared to normal tissues. Four miRNAs were 
significantly altered in both subgroups of patients, while 27 miRNAs were differentially 
expressed between PDAC and PVAC.
Although miRNA interaction networks were more complex and dense in PDAC 
than in PVAC, pathways enrichment analysis uncovered a functional overlapping 
between PDAC and PVAC. However, shared signalling events were influenced by 
different miRNA and/or genes in the two tumour entities.
Overall, specific miRNA expression patterns were involved in the regulation of a 
limited core signalling pathways in the biology landscape of PDAC and PVAC.
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INTRODUCTION
Pancreatic cancer is one of the most lethal malignancies 
which ranks fourth among the most prominent causes of 
cancer-related deaths in Western countries [1]. Although the 
exocrine pancreas consists of a very small ductal system, 
90% of pancreatic neoplasms are ductal in origin and are 
known as pancreatic ductal adenocarcinomas (PDAC) 
[2]. The propensity of PDAC to invade nearby organs and 
surrounding tissues, as well as the lack of effective means 
for screening and early detection, contribute to a significant 
delay in diagnosis, which thus usually occurs only after 
having reached advanced disease stages [3]. Consequently, 
the percentage of resectable patients is low and the average 
survival of these patients is approximately 12 to 20 months, 
with a high probability of relapse [2-4].
Adenocarcinoma of ampulla of Vater (PVAC) differs 
from PDAC in prognosis and in how it occurs. Based on 
its localization, PVAC is usually detected relatively early: 
the confluence of the common bile duct and the main 
pancreatic duct at the ampulla are signs that the tumours 
that arise at this location have the potential to obstruct 
two major organs and to result in relatively early onset of 
symptoms, which, most commonly, are biliary obstruction 
and pancreatitis. This explains why these lesions account 
for about half of all resectable pancreatic neoplasms, often 
before disease spreading to lymph nodes, and why PVAC 
patients have a consistently better survival than patients 
with PDAC [5-7]. However, the difference in survival is 
not entirely explained by the lower frequency of lymph 
node involvement in PVAC. In fact, the survival for node-
positive patients is still better than in PDAC and this 
difference may be explained by biological, particularly 
molecular, differences between the two cancer entities.
Recently, microRNAs (miRNAs) have grabbed a wide 
attention for their pivotal involvement in cancer development 
[8]. MiRNAs influence various biological processes, 
including cell proliferation, cell death and stress resistance, 
mainly by of gene expression [9]. The relationship between 
the miRNA expression dysregulation and the survival of 
patients affected by pancreatic adenocarcinoma was already 
reported in PDAC [10-13]. Conversely, little is known 
about the potential involvement of miRNAs in the onset and 
development of PVAC.
Our hypothesis is that several molecular characteristics 
of PDAC and PVAC, including the miRNA expression 
abnormalities, could be associated with distinctive pathologic 
features and clinical behaviours. Overall the aim of this 
study was to make a comparison between these two tumour 
entities on the pathogenetic level. For this purpose we defined 
differences and similarities of miRNA expression patterns 
of patients with PDAC and PVAC, up to respective target 
genes and signalling pathways. To this extent, we attempted 
to unravel the landscape of miRNA expression among 
PDAC and PVAC using co-expression networks as a proxy 
for highlighting the main differences between them and their 
healthy counterpart, as correlation networks are often used as 
discovery tools [14].
RESULTS
MiRNAs differentially expressed in tumour versus 
normal tissues from PDAC and PVAC patients
One hundred and one miRNAs, out of 1105 miRNAs 
assayed in our array experiments, were differentially 
expressed in PDAC tumours, compared to their adjacent 
normal tissue samples (68 over-expressed and 33 down-
regulated). MiR-887 was the most significantly altered 
miRNA (p=9.21x10-5), (Table 1).
In PVAC, 26 miRNAs were differentially expressed 
in tumours compared to normal tissues (Table 2). In details, 
7 miRNAs showed higher expression levels in tumour than 
normal tissues, whereas 19 miRNAs were down-regulated. 
In this cohort, miR-323-3p showed the most significantly 
altered expression in tumour samples (p=0.0042), (Table 2).
Table 3 reports differentially expressed miRNAs 
between tumour and normal tissues for both PDAC and 
PVAC. MiR-140-5p, miR-103, miR-1254, miR-199b-5p 
were significantly deregulated in both the subgroups of 
patients.
To ascertain the eventual existence of orthologous 
miRNAs, and to use them as internal methodological 
control, the human miRNAs that were found altered in 
PDAC and PVAC samples were checked in 71 other 
organisms probed in the microarray assay. All deregulated 
orthologous of human miRNAs showed a significant 
differential expression with similar fold-changes in these 
organisms, with the only exception of miR-182* and miR-
323-3p in the PDAC and PVAC subgroups of patients, 
respectively (Supplementary Table 1A-B).
MiRNAs differentially expressed in PDAC versus 
PVAC
In order to identify differentially expressed miRNAs 
between PDAC and PVAC patients, expression levels 
in paired tumour and normal tissues from PDAC and 
PVAC were compared. Twenty-seven miRNAs showed 
a significantly altered expression between PDAC and 
PVAC (Table 4). In details, 19 and 8 miRNAs were 
over- and down-regulated in PDAC compared to PVAC, 
respectively, with miR-889 and miR-323-3p showing the 
most relevant alteration (over- and down- expression, 
respectively) in PDAC vs PVAC.
Human miRNAs that were altered both in PDAC 
and PVAC were checked for the existence of orthologs 
in 71 organisms: all deregulated orthologs of human 
miRNAs showed a significant differential expression with 
close fold-changes, with the only exception of miR-323-3p 
(Supplementary Table 1C).
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Table 1: MicroRNA differentially expressed, by t-test, in paired normal and tumour tissues from patients with pancreatic 
ductal adenocarcinoma (PDAC)
miRNA Fold-change (T vs N) P-value miRNA Fold-change (T vs N) P-value
hsa-miR-887 1.43 9.21E-05 hsa-miR-199b-5p 1.57 0.0263
hsa-miR-125a-5p 12.94 0.0021 hsa-let-7d* -1.70 0.0268
hsa-miR-1321 -1.50 0.0024 hsa-miR-503 1.80 0.0272
hsa-miR-744 2.25 0.0037 hsa-miR-1244 2.46 0.0274
hsa-miR-500* 3.30 0.0039 hsa-miR-1254 -1.59 0.0279
hsa-miR-526a 1.34 0.0040 hsa-miR-221 3.62 0.0283
hsa-miR-214 4.24 0.0040 hsa-miR-27b* 2.02 0.0285
hsa-miR-1267 -2.26 0.0042 hsa-miR-708 3.33 0.0292
hsa-miR-181a 5.81 0.0043 hsa-miR-132 2.80 0.0298
hsa-miR-1249 -1.86 0.0048 hsa-let-7i 3.16 0.0306
hsa-miR-125a-3p 1.96 0.0048 hsa-miR-92b 1.74 0.0306
hsa-let-7e 12.59 0.0051 hsa-miR-24 6.33 0.0310
hsa-miR-1237 -1.68 0.0074 hsa-miR-199a-5p 4.90 0.0315
hsa-miR-181a* -2.60 0.0081 hsa-miR-29b 1.36 0.0318
hsa-miR-134 1.84 0.0083 hsa-miR-520a-3p -1.40 0.0331
hsa-miR-29b-1* 1.52 0.0083 hsa-miR-378* 1.66 0.0340
hsa-miR-132* -2.47 0.0084 hsa-miR-143 5.07 0.0340
hsa-miR-23a 7.12 0.0087 hsa-miR-16-2* -1.46 0.0340
hsa-miR-559 -2.59 0.0095 hsa-miR-181c* -2.26 0.0341
hsa-miR-339-5p 2.52 0.0098 hsa-miR-30b -1.92 0.0346
hsa-miR-154* -1.87 0.0101 hsa-miR-379 1.96 0.0352
hsa-miR-140-5p 1.65 0.0101 hsa-miR-136* -1.43 0.0353
hsa-miR-181b 4.82 0.0105 hsa-miR-183* -1.20 0.0373
hsa-miR-331-3p 2.56 0.0114 hsa-miR-100 2.43 0.0380
hsa-miR-92a 4.00 0.0124 hsa-miR-145 5.37 0.0380
hsa-let-7a 8.04 0.0141 hsa-miR-550 1.40 0.0392
hsa-miR-517* -1.40 0.0153 hsa-miR-26a 5.03 0.0395
hsa-miR-30c -1.81 0.0155 hsa-miR-423-3p 1.85 0.0405
hsa-miR-1301 2.14 0.0156 hsa-miR-373 -1.44 0.0412
hsa-miR-939 1.82 0.0159 hsa-miR-107 5.30 0.0416
hsa-miR-1227 -2.01 0.0164 hsa-miR-219-1-3p -1.66 0.0422
hsa-miR-487b -2.12 0.0170 hsa-miR-182* 1.24 0.0423
hsa-miR-502-3p 3.40 0.0171 hsa-miR-103 2.71 0.0425
hsa-miR-125b 4.06 0.0175 hsa-miR-558 -2.60 0.0427
hsa-miR-99b 2.86 0.0176 hsa-miR-23b 6.00 0.0438
hsa-miR-32 -1.20 0.0176 hsa-miR-99a 2.80 0.0440
(Continued)
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Networks of correlated miRNAs in normal and 
tumour tissue samples
PDAC
Networks of normal and tumour tissues were 
quite complex. The normal network was made of 98 
miRNAs, wired by 1.232 correlation edges (Figure 1A). 
The diseased network was composed by 100 miRNAs 
connected by 1.434 links (Figure 1B). One thousand 
and one hundred and ninety and 542 out of the 1434 
and 1232 links were preserved in the public dataset 
E-GEOD-60978. In details, 812 and 439 of these links had 
concordant correlation signs in PDAC and normal tissues, 
respectively, compared to our results (Supplementary 
Information #Sheet A).
In PDAC, normal and tumour networks preserved 
several unchanged correlations for most of their miRNAs: 
only 4 were not shared by the two networks, including 1 
(miR-348*) and 3 (miR-let-7d*, miR-1321, miR-373) out of 
the 98 and the 100 connected miRNAs in the normal and in 
the tumour networks, respectively. Conversely, 97 miRNAs 
were shared by the two networks including 65 linked by 
775 edges, which represented more than 50-60% of the total 
number of the edges of both the networks, and 32 miRNAs 
which did not share any link between the normal and the 
tumour networks (Supplementary Table 2A).
Two (miR-1321 and miR-373-3p) out of the 3 
miRNAs specifically belonging to the PDAC tumour 
network participate to the ABC transporters signalling 
pathway (Supplementary Table 3). Among the 
miRNAs shared between normal and tumour networks 
(Supplementary Table 2B), those that maintained the 
same links in the two networks (n=65) enriched 80 cancer-
related pathways, while 35 cancer-associated signalling 
events emerged for 7 out of the 32 miRNAs which did 
not share any links between normal and tumour networks. 
These miRNAs (miR-331-3p, miR-1246, miR-382, miR-
558, miR-181d, miR-1301, miR-559) exhibited high fold 
change values, and closely enriched 3 out of the 35 above 
mentioned signalling pathways.
As listed in Supplementary Table 2C, the most 
relevant signalling pathways for each subgroup of 
miRNAs were identified. In details, the pathways of the 
FOXO family and of MAPK were the most significantly 
impacted by the 65 shared miRNAs. The sets of 7 and 
65 aforesaid miRNAs equally enriched the regulation of 
nuclear SMAD2/3 pathway, while ERBB1 and c-MET 
signalling pathways were enriched mainy by the 7 
differentially connected miRNAs. The major pathways 
enriched by the 7 differentially connected miRNAs were 
the ERBB1 and c-MET signalling pathways. In addition, 
the Notch mediated HES/HEY network resulted to be 
enriched solely by the subgroup of the 7 miRNAs.
PVAC
Both normal-adjacent and tumour PVAC networks 
were much smaller than the corresponding PDAC networks. 
In particular, the normal network was made of 17 nodes and 
15 edges. Topologically, this network was characterized by 
a long chain of expression correlations among 7 miRNAs 
(miR-103, miR-889, miR-29b-2*, miR-410, miR-30b*, 
miR-1280 and miR-1228*), by 2 closed groups (triangles) 
including miR-548b-3p, miR-1254, miR-490-5p (triangle 
miRNA Fold-change (T vs N) P-value miRNA Fold-change (T vs N) P-value
hsa-miR-199b-3p 4.99 0.0178 hsa-let-7g 1.75 0.0444
hsa-miR-374a -2.39 0.0184 hsa-miR-361-5p 3.12 0.0445
hsa-miR-21 4.33 0.0185 hsa-miR-1246 2.28 0.0456
hsa-let-7d 4.73 0.0191 hsa-miR-625* -1.61 0.0457
hsa-miR-1304 -1.28 0.0196 hsa-miR-130a* -1.53 0.0457
hsa-miR-199a-3p 5.55 0.0198 hsa-miR-146a 2.67 0.0459
hsa-miR-498 1.51 0.0207 hsa-miR-663b 1.71 0.0459
hsa-miR-324-3p 1.72 0.0226 hsa-miR-10a 1.96 0.0464
hsa-miR-99b* 1.71 0.0229 hsa-miR-431 -1.42 0.0465
hsa-miR-181d 2.32 0.0238 hsa-miR-27b 2.62 0.0469
hsa-miR-411 -2.18 0.0242 hsa-miR-1259 -1.42 0.0476
hsa-miR-34a 2.81 0.0242 hsa-miR-222 3.74 0.0485
hsa-miR-195 3.24 0.0250 hsa-miR-30d -1.34 0.0487
hsa-miR-196a 1.34 0.0252 hsa-miR-337-3p -1.39 0.0494
hsa-miR-382 2.37 0.0262
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1) and miR-339-3p, miR-509-5p, miR-140-5p (triangle 2), 
respectively, and by two pairs of miRNAs (miR-551b*/miR-
30d* and miR-551a/miR-187*), (Figure 2A).
The tumour network was made of 21 miRNAs linked 
by 17 edges. No closed groups resulted, whereas it included 
a long chain of 8 miRNAs (miR-1280, miR-1228*, miR-
323-3p, miR-551a, miR-490-5p, miR-103, miR-1270 and 
miR-29b-2*), three shorter chains of 5 miRNAs (miR-
1254, miR-889, miR200c*, miR-410 and miR-548l) and 3 
miRNAs (miR-563/miR-30b*/miR-140-5p and miR-551b*/
miR-509-5p/miR-199b-5p), and one pair of miRNAs 
(miR-548b-3p/miR-30d*). In particular, the longest chain 
was made of an odd number (five) of consecutive inverse 
correlations (miR-1270, miR-103, miR-490-5p, miR-551a, 
miR-323-3p, miR-1228*), of which miR-103 was the only 
miRNA to be highly expressed (Figure 2B).
Comparing normal with tumour networks of 
PVAC samples, we found 15 miRNAs and only 1 edge 
in common, whereas 6 miRNAs (miR-1270, miR-
323-3p, miR-200c*, miR-548I, miR-563, miR-199b-
5p) were included only in the diseased network. By 
pathway enrichment analysis, 3 out of these 6 miRNAs 
were involved in the LICAM interactions process 
[miR-199b-5p (AKN2, CLTC, LAMC1), miR-323a-3p 
(ANK2, DCX, KCNQ3, KIAA1598, LAMC1, NRP2, 
SCN2A, SPTBN1), miR-563 (ITGA9, SPTBN2)], and 
in the axon guidance signalling pathway [miR-199b-5p 
(ANK2, ARHGEF12, CLTC, GSK3B, LAMC1, MYH9, 
Table 2: MicroRNA differentially expressed, by t-test, in paired normal and tumour tissues from patients with 
adenocarcinoma of papilla of Vater (PVAC)
miRNA Fold-change (T vs N) P-value
hsa-miR-323-3p 1.59 0.0042
hsa-miR-525-5p -1.22 0.0111
hsa-miR-199b-5p -1.25 0.0120
hsa-miR-30d* -1.27 0.0130
hsa-miR-339-3p -3.35 0.0202
hsa-miR-490-5p -1.34 0.0208
hsa-miR-1305 -1.69 0.0232
hsa-miR-1270 -1.35 0.0273
hsa-miR-1254 -2.22 0.0292
hsa-miR-643 1.55 0.0303
hsa-miR-29b-2* 1.73 0.0309
hsa-miR-509-5p -1.10 0.0316
hsa-miR-200c* 1.38 0.0335
hsa-miR-410 -1.51 0.0337
hsa-miR-563 -1.30 0.0343
hsa-miR-187* -1.49 0.0345
hsa-miR-889 -6.53 0.0352
hsa-miR-551a -1.22 0.0394
hsa-miR-30b* -1.58 0.0397
hsa-miR-140-5p 1.43 0.0399
hsa-miR-1280 -3.97 0.0401
hsa-miR-548b-3p 1.29 0.0423
hsa-miR-1228* -4.07 0.0432
hsa-miR-551b* -1.17 0.0442
hsa-miR-548l -1.37 0.0479
hsa-miR-103 15.43 0.0485
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PLXNA2, RGMA, RGMB, RND1, SEMA6A, SRGAP2), 
miR-323a-3p (ANK2, CLASP1, CREB1, DCX, ENAH, 
KCNQ3, KIAA1598, KRAS, LAMC1, MET, NRP2, 
PAK7, PITPNA, ROCK1, SCN2A, SEMA6D, SPTBN1, 
SRGAP1), miR-563 (COL1A2, COL3A1, ITGA9, 
SPTBN2)]. Conversely, miR-1270, miR-200c*, miR-548I 
did not enrich any pathway related to pancreatic cancer.
Focusing on miRNAs with elevate fold-change 
values in the two networks, namely on miR-1254 (FC=-
2.22), miR-1228* (FC=-4), miR-1280 (FC=-3.97), miR-
889 (FC=-6.53) and miR-103 (FC=15.4), we noticed 
that the only common correlation was that between miR-
1228* and miR-1280. MiR-889 was directly linked to 
and inversely correlated with miR-103 in normal tissues, 
while it was directly correlated with miR-1254 in tumour 
tissues. However, only miR-103 was directly involved in 
the regulation of pancreatic cancer-associated processes: 
E-cadherin signalling events (CDH1), TGF beta signalling 
pathway (TGFBR2, APC, CDH1, CREBBP, EP300, 
SMAD3, TSC2), and altered TFG-beta SMAD dependent 
signalling (TGFBR2, SMAD3, and FBXW7).
Finally, the two triangles of miRNAs were peculiar 
to the normal network only, and among their validated 
target genes retrieved by miRTarBase, miRWalk and 
TarBase 7 there were DICER1 (controlled by miR-
548b-3p), TP53 and CDH1 (regulated by miR-140-5p, 
belonging to the triangle 2). These genes are mostly 
involved in the perturbation of DICER1, p53, p21, and 
E-cadherin pathways.
Networks of correlated miRNAs in tumour versus 
normal tissue samples
PDAC
A correlation-based network was built with the 
differentially expressed miRNAs between healthy-adjacent 
and tumour tissues, and drawn in Figure 3. This was clustered 
in 5 highly cohesive subgroups of miRNAs: cluster 1 with 
38 miRNAs (density: 0.504, p-value: 1.405E-12); cluster 2 
with 18 miRNAs (density: 0.608, p-value: 2.556E-5); cluster 
3 with 5 miRNAs (density: 0.700, p-value: 0.007); cluster 
4 with 4 miRNAs (density: 0.833, p-value: 0.025), and 
cluster 5 with 8 miRNAs (density: 0.571, p-value: 0.077). 
The complete lists of miRNAs belonging to each cluster is 
reported in Supplementary Table 4.
A ranking of these miRNAs was assessed by 
the calculation of an array of topological indices (cf. 
Methods). We verified that 9 miRNAs (miR-34a, miR-
125a-5p, miR-199a-5p, miR-181a, miR-30c, miR-30b, 
miR-339-5p, miR-214, miR-411) belonging to cluster 1 
Table 3: MicroRNA showing significant or a trend of alteration in tumour compared to normal tissues samples in both 
pancreatic ductal adenocarcinoma (PDAC) and adenocarcinoma of papilla of Vater (PVAC)
PDAC PVAC
Fold-change (T vs N) P-value Fold-change (Tvs N) P-value
hsa-miR-140-5p 1.65 0.0101 1.43 0.0399
hsa-miR-103 2.71 0.0425 15.43 0.0485
hsa-miR-1254 -1.59 0.0279 -2.22 0.0292
hsa-miR-199b-5p 1.57 0.0263 -1.25 0.0120
hsa-miR-1244 2.46 0.0274 7.48 0.0579
hsa-miR-146a 2.67 0.0459 5.02 0.0593
hsa-miR-30d -1.34 0.0487 -4.56 0.0556
hsa-miR-1259 -1.42 0.0476 1.25 0.0606
hsa-miR-1304 -1.28 0.0196 1.15 0.0828
hsa-miR-525-5p -1.18 0.0837 -1.22 0.0111
hsa-miR-643 -1.13 0.0903 1.55 0.0303
hsa-miR-1207-5p 2.08 0.0722 2.08 0.0771
hsa-miR-138-1* 1.54 0.0807 2.10 0.0526
hsa-let-7f-1* -1.58 0.0589 -1.51 0.0623
hsa-miR-629* -2.25 0.0716 -5.11 0.0722
hsa-miR-1260 -1.63 0.0809 -2.02 0.0982
hsa-miR-302a* -1.64 0.0808 1.24 0.0546
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were top-five ranked for at least one topological index, and 
that 3 of these (miR-181a, miR-30c, miR-30b) exhibited 
the highest values for more than one topological index 
(Supplementary Table 5A).
The genes targeted by miRNAs belonging to cluster 
1 were mostly controlled by 25 out of 38 miRNAs, and a 
few of these targeted the most genes (Supplementary Table 
5B). By pathway enrichment analysis, the altered TGF-
beta signalling pathway was regulated by TGFBR2 (miR-
21, miR-214), SMAD3 (miR-21, miR-146a, miR-30b, 
miR-195, miR-503), and SMAD4 (miR-21, miR-146a, 
miR-181a, miR-181a*, miR-181b, miR-181c*, miR-181d) 
(Supplementary Table 5C).
PVAC
The network wiring the 26 deregulated miRNAs 
of PVAC tumours was drawn in Figure 4. The clustering 
algorithm identified only one cluster, which included 
miR-1254, miR-200c*, miR-1270, miR-889, miR-
551b*, miR-103, miR-29b-2* and miR-548I (density: 
0.533, p-value: 0.004) and so MiR-548I, miR-103 and 
miR-1254 worked as “seeding nodes” of the clustering 
method, and miR-29b-2-5p was directly correlated with 
two of the three seeding nodes (miR-103 and miR-1254). 
Additionally, 10 miRNAs were correlated in pairs: miR-
551a/miR563, miR-410/miR30b*, miR-548b-3p/miR-
Table 4: MicroRNA differentially expressed in paired normal and tumour tissues, by t-test, in pancreatic ductal 
adenocarcinoma (PDAC) compared to adenocarcinoma of papilla of Vater (PVAC)
miRNA Fold change (PDAC vs PVAC) P-value
hsa-miR-323-3p -2.13 0.0006
hsa-miR-199b-5p 2.04 0.0024
hsa-miR-1259 -1.93 0.0024
hsa-miR-1304 -1.50 0.0067
hsa-miR-550 2.30 0.0130
hsa-miR-122 -1.55 0.0145
hsa-miR-302a* -2.08 0.0157
hsa-miR-922 -1.99 0.0183
hsa-miR-125a-3p 2.33 0.0195
hsa-miR-643 -1.83 0.0236
hsa-miR-1301 2.50 0.0249
hsa-miR-518c* 1.41 0.0259
hsa-miR-889 7.42 0.0317
hsa-miR-516a-3p 1.66 0.0332
hsa-miR-939 1.69 0.0335
hsa-miR-125b-1* 1.99 0.0336
hsa-miR-187* 1.73 0.0339
hsa-miR-18b* 3.09 0.0349
hsa-miR-548b-3p -2.07 0.0369
hsa-miR-1270 1.54 0.0369
hsa-miR-593 1.31 0.0382
hsa-miR-410 1.64 0.0415
hsa-miR-551b* 1.58 0.0435
hsa-miR-23b* 1.60 0.0452
hsa-miR-490-5p 1.86 0.0456
hsa-miR-339-3p 2.78 0.0457
hsa-miR-450a 1.58 0.0496
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323-3p, miR-1305/miR-509-5p, miR-30d*/miR-1280. 
The remaining 8 miRNAs did not show any significant 
correlation with any other miRNAs.
We found that 3 out of the 8 miRNAs (miR-103, miR-
29b-2*, miR-200c*) controlled several genes (Supplementary 
Table 6A), which turned out to enrich different signalling 
pathways: TGF beta pathway (TGFBR2, APC, CDH1, 
CREBBP, EP300, SMAD3, TSC2), altered TFG-beta SMAD 
dependent signalling (TGFBR2, SMAD3, FBXW7), p53 
pathway and transcriptional activation of cell cycle inhibitor 
p21 (TP53), and E-cadherin signalling events (CDH1), 
(Supplementary Table 6B).
Networks matching
Four miRNAs were significantly deregulated both in 
PDAC and in PVAC. The regulation directions of miR-103 
and miR-1254 were concordant, yet with different fold-
changes values: miR-103 (PDAC: FC = 2.71; PVAC: FC 
= 15.43) and miR-1254 (PDAC: FC = -1.59; PVAC: FC 
=2.22). MiR-140-5p and miR-199b-5p were mildly altered 
in both the tumour entities, with opposite directions of 
regulation for the latter miRNA [miR-140-5p: FC=1.65 
(PDAC), FC=1.43 (PVAC); miR-199b-5p: FC=1.57 
(PDAC); FC=  -1.24 (PVAC)].
miR-103
In PDAC, miR-103 was significantly correlated with 
17 miRNAs that were not regulated less than 2 folds in 
tumour compared to normal tissues. Almost all correlations 
were positive, except from those involving miR-1227, miR-
1267 and miR-558 (Figure 5). It is worth noticing that 15 
on 17 miRNAs fell in the cluster 2 (Supplementary Table 
4). Topologically, miR-92a was in the top-ten ranked for 
betweenness (0.0499), while let-7a, let-7d and miR-145 were 
the most important in terms of correlation coefficient values 
(0.857, 0.727 and 0.705, respectively). MiR-103 targeted 
directly FBXW7, VCP, CHD1, PCDH17, HIP1, TGFBR2, 
Figure 1: Correlation network between microRNA altered in tissue samples from patients with pancreatic ductal 
adenocarcinoma (PDAC). (A) Normal tissues; global geometric attributes: connected components 1, network diameter 6, network 
centralization 0.27, shortest paths 9506 (100%), characteristic path length 2.35, average number of neighbours 25.14, network density 0.26, 
and network heterogeneity 0.77. (B) Tumour tissues; global geometric attributes: connected components 3, network diameter 6, network 
centralization 0.32, shortest paths 89.38 (90%), characteristic path length 2.18, average number of neighbours 28.68, network density 0.29, 
and network heterogeneity 0.72. Direct and inverse correlations are in red and blue, respectively.
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TNF genes, while indirectly, through 11 of its 17 neighbour 
miRNAs, several more genes (Supplementary Table 7A). The 
majority of these genes were controlled by let-7d-5p, let-7a-
5p, let-7e and miR-92a, and CDKN2A, FBXW7, TP53 and 
MYC were targeted by the most miRNAs. Some of the target 
genes, i.e., TGFBR2, SMAD3, SMAD4 regulated by (miR-
103, miR-92a, miR-26a-5p, miR-145-5p, miR-143, let-7d-5p, 
miR-23a-3p, miR-107) turned out to participate to the TGF-
beta signalling pathway in PDAC (Supplementary Table 7B).
In PVAC, miR-103 was positively correlated only 
with miR-551b*, which was in turn positively correlated 
with miR-29b-2* and negatively with miR-889 (Figure 
4). About predicted targets, the seven genes mentioned 
above were regulated by miR-103, whereas 23 genes were 
targeted by miR-29b-2* (Supplementary Table 6A). These 
genes over-represented a number of signalling pathways: 
TGF beta pathway (TGFBR2, APC, CDH1, CREBBP, 
EP300, SMAD3, TSC2), altered TFG-beta SMAD 
dependent signalling (TGFBR2, SMAD3, FBXW7), 
p53 pathway and transcriptional activation of cell cycle 
inhibitor p21 (TP53), and E-cadherin signalling events 
(CDH1), (Supplementary Table 6B).
miR-1254
In PDAC, miR-1254 was directly correlated only 
with let-7g, which in turn was correlated with miR-221 
and miR-92b. MiR-1254 did not target directly any known 
genes associated with the disease, and no target genes 
were found to be regulated by miR-92b. Conversely, let-7g 
was confirmed to target 9 critical genes (TP53, CDKN2A, 
FBXW7, FN1, MYC, TBX5, GLI1, TNF, ERCC4), 
and miR-221 resulted to control only 4 of these (TP53, 
CDKN2A, MYC, TNF).
In PVAC, miR-1254 was negatively correlated only 
with miR-200c*, which in turn was directly correlated with 
miR-29b-2* and miR-1270 (Figure 5). As for miR-1254, 
no target genes of miR-1270 were reported to be directly 
associated to the disease. Conversely, miR-200c* and 29b-2* 
targeted several genes listed in Supplementary Table 5A.
Among the enriched signalling pathways, it emerges 
that the DNA damage repair pathway was shared by 
PDAC and PVAC. In details, the neighbourhood of miR-
1254 was more involved in the regulation of this pathway: 
both miR-200c* (correlated to miR-1254 in PVAC) and 
Figure 2: Correlation network between microRNA altered in tissue samples from patients with adenocarcinoma of 
papilla of Vater (PVAC). (A) Normal tissues; (B) tumour tissues. Direct and inverse correlations are in red and blue, respectively.
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let-7g (correlated to miR-1254 in PDAC) targeted EP300 
and ERCC4 genes, respectively.
miR-140-5p
In PDAC, miR-140-5p was correlated with 4 
miRNAs (miR-939, miR-625*, miR-1249 and miR-27b-
3p). Genes associated with the pancreatic cancer core 
signalling pathway were controlled only two of these 
miRNAs, namely miR-140-5p and miR-27b-3p. As 
shown in Supplementary Table 8A, these two miRNAs 
were predicted to regulate the same cancer-related 
target genes. By pathway enrichment analysis, several 
signalling pathways were uncovered: p53 pathway, 
the transcriptional activation of cell cycle inhibitor 
p21 (TP53), E-cadherin signalling events (CDH1), 
(Supplementary Table 8B).
Figure 3: Correlation network between microRNA altered in tumour compared to normal tissue samples from patients 
with pancreatic ductal adenocarcinoma (PDAC). Direct and inverse correlations are in red and blue, respectively.
Figure 4: Correlation network between microRNA altered in tumour compared to normal tissue samples from patients 
with adenocarcinoma of papilla of Vater (PVAC). Direct and inverse correlations are in red and blue, respectively, and seeding 
nodes are colored in yellow.
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Conversely, miR-140-5p did not correlate with any 
miRNA significantly deregulated in tumours, compared to 
normal tissues in PVAC patients. Therefore, the regulation 
of the above-mentioned signalling pathways might be 
imputed only to miR-140-5p in PVAC.
miR-199b-5p
In PDAC, miR-199b-5p was characterized by relevant 
topological values: average shortest path (3.8865) and 
topological coefficient (0.5238). Its expression was correlated 
with 3 miRNAs: directly with both miR-520a-3p and let-7d*, 
and inversely, with miR-196a. MiR-199b-5p did not directly 
target any known PDAC gene. However, part of its closest 
neighbourhood regulated several genes (Supplementary Table 
9A). By pathway enrichment analysis, several signalling 
pathways were uncovered: p53 pathway, the transcriptional 
activation of cell cycle inhibitor p21 (TP53), E-cadherin 
signalling events (CDH1), (Supplementary Table 9B).
Conversely, miR-199b-5p did not correlate with any 
miRNAs in the PVAC network.
MiRNAs differentially expressed in PDAC versus 
PVAC
MiR-889 (FC=7.4) and miR-323-3p (FC=-2.12) 
were the most discriminating miRNAs between PDAC 
and PVAC. No genes associated with pathways involved 
in PDAC/PVAC were found to be targeted by miR-889, 
whereas for miR-323-3p two validated targets genes were 
identified (NTRK1 and TNF), which were involved in the 
biological process of pain perception (p= 1.421E-2).
The 27 miRNAs that resulted significantly altered 
between the matched-pairs of tissues of PDAC and PVAC 
significantly influenced the Wnt and Hedgehog signalling 
pathways, other than MAPK, ErbB1 and Notch (already 
associated to PDAC) and TFG-Beta and p53 (already 
associated to PVAC) signalling pathways.
DISCUSSION
In the last years, several studies have investigated 
miRNA expression alterations in pancreatic cancer. 
However, the most were focused on PDAC while only 
a few investigated the expression profiles of miRNA in 
other pancreatic diseases, including PVAC [15-18].
Our study was designed to dig miRNA expression 
alterations out of PDAC or PVAC, and to figure out if these 
could be associated with distinctive signalling pathways 
in turn reflecting differences in pathogenesis and clinical 
behaviours of these two different entities of cancer.
Overall, PDAC and PVAC showed different 
miRNA alterations, with PDAC being more deregulated 
and probably a more complex disease. Changes in 
miRNA expression levels displayed a different direction 
in the two subgroups of patients. In PDAC samples, 
68 out of the 101 altered miRNAs (67%) were over-
expressed in tumours compared to normal tissues. These 
miRNAs may function as oncogenes promoting cancer 
development by negatively regulating tumour suppressor 
genes, whose aberrations were known to synergistically 
accelerate the progression of pancreatic carcinogenesis 
through pre-neoplastic lesions to adenocarcinoma [19, 
20]. Conversely, more miRNAs were down-regulated in 
tumours compared to normal tissue samples from PVAC 
patients (19/26, 73% vs 7/26, 27%); the high percentage 
Figure 5: MiR-103 neighbourhoods in pancreatic ductal adenocarcinoma (PDAC). Direct and inverse correlations are in red 
and blue, respectively.
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of under-expressed miRNAs in PVAC may function 
as tumour suppressor genes and may inhibit cancer by 
positively regulating oncogenes.  With respect of the 
molecular changes, ampullary cancer was seen to be 
more similar to the intestinal cancer and characterized by 
alterations in oncogenes rather than in tumour suppressor 
genes [21, 22].
By comparing miRNA expression alterations 
in PDAC and PVAC we found that only 4 miRNAs 
(miR-140-5p, miR-103, miR-1254, miR-199b-5p) 
were deregulated in both the subgroups of patients. 
Conversely, a limited overlap between miRNAs 
significantly altered in both PDAC and PVAC emerged, 
suggesting the existence of tumour-specificity for 
miRNAs alteration in different entities of pancreatic 
cancer.
Furthermore, the expression of 27 miRNAs was 
significantly different in PDAC compared to PVAC. 
One of these, miR-323-3p, was shown to influence the 
biological process of pain perception. Pain has long 
been considered the most common symptom in patients 
with pancreatic disorders, and its presence in newly 
diagnosed patients with potentially operable pancreatic 
cancer is a predictor of resectability and survival [23]. 
However, the pattern of pain sensation process does 
not characterized different pancreatic tumours equally, 
while it was reported to depend on tumour type, 
anatomic localization and dignity of different pancreatic 
diseases [24]. This miRNA was already reported in 
literature for its association with painful events, such 
as ectopic pregnancy. Authors found that miR-323-
3p was significantly increased in women experiencing 
abdominal pain/cramping and that received a diagnosis 
of ectopic pregnancy compared to those with intrauterine 
pregnancy and spontaneous abortion [25]. In our series 
miR-323-3p was altered in the opposite direction, so 
we can hypothesize that it can influence the pattern of 
pain sensation in PDAC and PVAC which clinically 
distinguishes these two tumour entities.
In order to identify the most relevant miRNAs 
in each tumour entity, and the signalling pathways in 
which there are involved, expression data were used to 
wire correlation networks both for PDAC and PVAC. 
MiRNA interactions in normal and tumour tissues 
were first taken into account in order to highlight the 
main alterations characterizing the two tissue types. 
Afterwards, with the intent to uncover those alterations 
that further exalt the differences between normal and 
tumour, the correlation networks were built by using 
miRNAs differentially expressed in matched pairs of 
tissues. By this approach, it was possible to identify 
three main subgroups of miRNAs either in PDAC and 
PVAC: miRNAs present only in the diseased network, 
those shared between normal and tumour network, and 
finally the most relevant miRNAs significantly altered 
in tumour compared to normal tissues.
In PDAC the diseased network was denser, more 
reachable and complex compared to the normal one. Indeed, 
it exhibited a shorter diameter, a higher centralization and 
a greater number of node neighbours, even though its local 
betweenness centrality was, in the average, lower than that 
of the nodes of the normal network. In general, the increased 
complexity of tumour compared to normal network might 
reflect the substantial reorganization of the controlling 
mechanisms fulfilled by these miRNAs in cancer. By 
comparing normal and tumour networks, we found that only 
a few miRNAs were not shared between the two networks, 
including 3 out of the 100 miRNAs connected in the 
tumour network (let-7d*, miR-1321, miR-373). By pathway 
enrichment analysis, ABC transporters signalling pathway 
emerged as regulated by miR-1321 and miR-373-3p.
Drug resistance is a major obstacle to the successful 
chemotherapy, and the ATP-binding cassette (ABC) 
transporter family members are the most common genes 
involved in the cancer multidrug resistance [26, 27]. 
We found that eight ABC proteins were targeted by the 
miR-1321 and miR-373-3p in PDAC network. Three out 
of them (ABCC2, ABCC5, ABCC8) have been already 
described for their association with drug resistance 
in pancreatic cancer [28-33]. Furthermore, a possible 
involvement of ABCC8 in pancreatic adenocarcinoma 
development and progression was recently reported [29].
By comparing normal and tumour networks in 
PDAC, we identified 97 miRNAs in common between the 
two networks including a core set of miRNAs that is partly 
or completely modulated by the disease (65 miRNAs 
which preserved unchanged correlations), and another 
set of 32 miRNAs which do not share any links between 
normal and tumour networks. In the latter subgroup we 
also identified 7 miRNAs characterized by high fold-
change values. Among the most relevant pathways 
regulated by these subsets of miRNAs, we hypothesized 
that the Notch–mediated HES/HEY network, enriched 
only by the 7 miRNAs not sharing links, might be involved 
in the tumor progression compared to the pathways 
enriched by miRNAs belonging also to the subset of 65 
miRNAs, which instead might be involved in the onset 
of the disease. In addition, according to the score values 
associated to each pathway, it was possible to suppose 
a sequential involvement for these signalling events in 
the carcinogenesis of pancreatic cancer: FOXO family 
and MAPK signalling pathways might intervene before, 
followed by regulation of nuclear SMAD2/3 signalling, 
while molecular events mediated by ERBB1 and c-MET 
might be deregulated later during the development of 
pancreatic cancer.
The importance of all these signalling pathways was 
supported by the literature. Most studies have revealed that 
the Notch activation has an oncogenic role for pancreatic 
cancer and is involved in cell proliferation, apoptosis, 
migration, invasion, metastases, and angiogenesis [34-41]. 
On the other hand, the mammalian forkhead members of 
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the class O (FOXO) transcription factors are implicated as 
tumour suppressors in the regulation of several biological 
processes, including stress resistance, metabolism, cell 
cycle, apoptosis and DNA repair [42-48]. In relation to 
MAPK signalling, previous studies have shown that 
MAPK activity is required for PanIN formation and occurs 
early during the pancreatic transformation [49]. Similarly, 
SMADs have been identified as proteins that transduce 
the upstream signalling from TGF-Beta superfamily, 
thereby influencing cell proliferation, differentiation, and 
apoptosis [50, 51]. Finally, both the signalling pathways 
mediated ErbB1 and c-MET have been described for their 
associations with a more aggressive phenotype and poor 
prognosis in patients with pancreatic adenocarcinoma [52, 
53].
Finally, the interactions network between miRNAs 
differentially expressed in tumour compared to normal 
tissues from PDAC corroborated the noteworthy 
complexity feature of the network and reflected the 
complexity of the disease at issue. Due to its size, this 
network has been clustered into five highly cohesive 
groups of miRNAs. The first cluster seemed to have a 
relevant role since a subset of miRNAs belonging to 
this cluster emerged as the top-five ranked for at least 
one topological index. Pathway analyses emphasized the 
importance of the signalling events mediated by TGF-beta 
in PDAC.
Disruption of normal TGF-beta pathway has been 
implicated in the pathogenesis and progression of pancreatic 
cancer, where it may play a dual effect as tumour suppressor 
and as a tumour promoter in normal and malignant cells, 
respectively [50]. In details, our finding showed that TGF-
beta pathway was influenced by several miRNAs (miR-21, 
miR-214, miR146a, miR-30b, miR-195, miR503, miR181a-
a*-b-c*-d) on 3 main genes (TFGBR2, SMAD3, SMAD4) in 
PDAC.
Networks analysis allowed to identify three main 
subgroups of miRNAs also in PVAC. Overall, the miRNAs 
and the signalling pathways closed to the tumour network did 
not correspond to those highlighted in the diseased network 
wired for PDAC in PVAC. Conversely, a partial overlap 
in relation to TGF-beta signalling events emerged from 
enrichment analysis based on either miRNAs shared between 
normal and tumour network and on those significantly altered 
in tumour compared to normal tissues samples in PVAC.
In details, the three miRNAs present only in the 
diseased network (miR-199b-5p, miR-323a -3p, miR-563) 
regulated a number of target genes involved in the LICAM1 
and AXON guidance signalling pathways. Other authors 
reported that the increase of LICAM1 expression levels 
were associated with the chemo resistance and migratory 
phenotype of pancreatic cancer cells, and showed the 
significant correlation with the degree of perineural invasion 
of the tumour and the clinical course of patients [54, 55]. 
Similarly, the signals transmitted along the axons have 
been recently confirmed to be associated with diffusion and 
metastasis in pancreatic cancer [56, 57].
Among the miRNAs shared between the two 
networks, we found that the only common correlation 
was that between miR-1228* and miR-1280; although 
Schopman et al. showed that the sequence annotated 
as miR-1280 is likely to be a fragment of a tRNA [58], 
these two miRNAS were likely to initiate and drive 
the correlation chains for normal and tumour tissues, 
respectively. In relation to miR-889, even if this miRNA 
did not target any genes associated with pancreatic 
cancer, its changes in either direction and neighbouring 
in the two networks may be the sign of an important 
change in the functional targeting between healthy 
and tumour tissues. Conversely, miR-103 was the only 
miRNA among those with a high fold-change value that 
targeted genes associated with pancreatic cancer; it was 
in a prominent topological position in normal network, 
whereas it was the only miRNA to be highly expressed 
and is likely to drive the longest chain of consecutive 
inverse correlations in the tumour network. We found 
that miR-103 influenced, TFG-beta pathways (TGFBR2, 
APC, CDH1, CREBBP, EP300, SMAD3, TSC2), altered 
TGF-beta SMAD dependent signalling (TGFBR2, 
SMAD3, FBXW7), and E-cadherin signalling events 
(CDH1) in PVAC.
Noteworthy, miR-103 seemed to have a peculiar 
role even in PDAC, where it was an important hub of 
the interactions network between miRNAs differentially 
expressed in tumours compared to normal tissues; 
therefore, even if it did not directly modulate many genes, 
it might exert a relevant influence to the target genes of its 
neighbour miRNAs, most of which belong to the cluster 
2 of the network. The shared centrality of miR-103 in the 
two cancer entities was accompanied by an overlap in 
the signalling pathways associated with this miRNA. As 
uncovered by enrichment analysis, miR-103 influenced 
the signalling pathway mediated by TFG-Beta in PDAC 
and PVAC. However, while in PDAC more miRNAs 
connected to miR-103 regulated specific target genes, 
in PVAC miR103 exerted its direct influence on a larger 
number of genes.
In relation to these genes, recent studies have 
revealed a molecular association between TGF-beta/
SMADs signalling pathways and tuberin (TSC2), a 
tumour suppressor gene involved in cell growth and 
differentiation, and in cell cycle progression [59]. 
SMADs were also reported to interact with CBP and 
p300, proteins having histone acetyl transferase and 
histone deacetylase activities, and to play an important 
role in cell proliferation and differentiation [60]. 
The association of SMAD2 and SMAD3 with APC 
gene was reported to contribute as antagonist of the 
events mediated by TGF-beta [61]. Within the SMAD 
signal transduction pathway, FBXW7 gene enhances 
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TGFβ-dependent transcription by inactivating the 
repressor transcriptional repressor TGIF1 [62-64]. 
Furthermore, CDH1, the adhesion molecule involved 
in cell-to-cell cohesion, cell-to-cell recognition, and 
epithelial polarity, is known to be regulated by TGFβ 
in pancreatic ductal adenocarcinoma [65]. It is involved 
in tumour progression and in prognosis of patients with 
pancreatic cancer [66-71].
Evaluation of interactions network between 
miRNAs differentially expressed in tumour compared 
to normal pancreatic tissues from PVAC highlighted 
that other two miRNAs (miR-200c* and miR-29b-2*) 
contributed with miR-103 to enriching TFG-beta and 
altered TGF-beta SMAD dependent, signalling events 
E-cadherin, pathway and signals mediated by p53 and 
p21. Once again, data showed an overlap in the regulation 
of TGF beta pathway. However, it must be stressed that 
the signalling events at issue were regulated by different 
miRNAs and in turn by different target genes in PVAC 
compare to PDAC.
Noteworthy, another peculiarity in PVAC 
concerned the topological organization of miRNAs 
forming two closed groups in the normal network. 
Since these closed groups did not persist in the diseased 
network, they might be the sign of an important change 
in functional targeting between healthy and tumour 
tissues. Furthermore, it was hypothesized that these 
closed groups can identify “functional collaborators”: 
genes and biological processes regulated by miRNAs 
can be associated with each other; alternatively it was 
possible to speculate that the effects of a miRNA on 
target genes and their respective signalling pathways 
occur according to miRNA expression, which in turn 
may depend on the correlation between the expression 
levels of miRNAs in the closed groups [72-74]. In 
details, miR-548b-3p of the first closed group regulated 
DICER1, involved in the biogenesis of miRNAs 
themselves;Recently, a potential oncogenic role for 
DICER1 in pancreatic cancer initiation was also 
reported [75-77]. On the other hand several genes were 
influenced by miR-140-5p of the second closed group. 
These genes significantly enriched the signalling events 
mediated by p53, p21 and E-cadherin. The importance 
of these pathways  in pancreatic carcinogenesis are well 
documented [68, 69, 72, 78, 79].
In relation to the pathways influenced by miR-140-
5p, a difference between PDAC and PVAC emerged:miR-
140-5p acts independently and directly in PVAC, whereas 
its neighbour miR-27b-3p regulates of the same signalling 
events in PDAC.
In addition, we found that the signalling pathways 
mediated by miR-140-5p were influenced also by miR-
199b-5p in PDAC: its three neighbours (miR-196a, let7d*, 
miR-520a-3p) regulated several target genes (TP53, 
CDH1, TSC2, CREBBP, TGFBR2, SMAD3, SMAD4) 
involved in these signalling events.
On the other hand, miR-1254 exemplified the case 
of a miRNA involved in the same signalling pathways 
in the two entities of pancreatic cancer, albeit thought 
different neighbours influencing different target genes. 
Indeed, either ERCC4 and EP300, targeted by let-
7g and miR-200c* in PDAC in PVAC respectively, 
influenced the DNA damage repair pathway. Evidences 
have revealed that ERCC4 expression levels are 
Figure 6: Main signalling pathways, together with miRNAs and respective target genes, emerged from microRNA 
co-expression networks in pancreatic ductal adenocarcinoma (PDAC) compared to Vater’s papilla adenocarcinoma 
(PVAC). Shared signalling events, regulated by different miRNAs and/or genes in PDAC and PVAC, are highlighted in red.
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correlated with cancer risk, progression, response 
to chemotherapy, and clinical outcome of different 
tumours, such as head and neck cancer, suggesting 
that altered ERCC4 expression may lead to altered 
DNA repair capacity, thereby modulating cancer 
susceptibility [80]. Similarly, EP300 is a transcriptional 
co-activator that mediates many transcriptional events 
including DNA repair [81].
Finally, the enrichment analysis was performed by 
using the 27 miRNAs significantly altered in matched pairs 
of tissues from PDAC compared to those from PVAC, in 
order to predict a role for miRNAs in distinguishing between 
PDAC and PVAC. A part from conforming the involvement 
of miRNAs in some of the pathways previously associated 
with PDAC or PVAC, our findings uncovered the regulation 
of the Wnt and the Hedgehog signalling pathways. Wnt 
signalling events were reported in the literature for their 
association with the carcinogenesis and progression of 
pancreatic cancer [82]. Similarly, activation of Hedgehog 
signalling pathway influences cell proliferation and cell cycle 
and thus has a role for initiation of pancreatic cancer either 
alone or in a K-Ras dependent way [83, 84].
In general, PDAC was characterized by a more 
consistent miRNA alteration compared to PVAC, and a 
more complex interactions networks were found either for 
miRNAs connected in tumour tissues and for those altered in 
tumours compared to normal pancreatic samples. However, 
with few exceptions especially in relation to the signalling 
events regulated by miRNAs connected only in the tumour 
networks and for those emerged from miRNAs shared 
between tumour and normal networks, our findings show a 
good overlap between the signalling pathways influenced by 
miRNAs in the two tumour types. Nevertheless, the shared 
signalling pathways were regulated by different miRNAs 
and/or genes in PDAC and PVAC (Figure 6).
Overall our findings reflect the specificity of 
miRNAs expression patter within different entities of 
pancreatic cancer, and suggest a role for these molecules 
in the regulation of a limited core signalling pathways in 
the biology landscape of PDAC and PVAC.
Father studies are needed to corroborate our data 
from co-expression networks. In details, the biological 
effect of specific miRNAs should be functionally 
validated in vitro to verify the interaction between miRNA 
and mRNA target, their co-expression, and their effect on 
the predicted protein expression up to the alteration of 
respective signalling pathways.
MATERIALS AND METHODS
MiRNA profiling datasets
The main cohort of this study is made of two groups 
of patients, 9 PDAC and 4 PVAC, enclosed in our previous 
miRNAs expression profiling study on matched-pairs of 
normal and tumour tissues samples from 17 patients with 
different histological types of pancreatobiliary cancer 
(including, apart from PDAC and PVAC, adenocarcinoma 
arising from the biliary epithelium) [85].
Tissue samples were obtained from patients who 
underwent pancreatic resection for PDAC or PVAC, 
and before any chemotherapy had been initiated. In 
details, specimens were harvested during surgery after 
extemporaneous anatomopathological test for evaluation of 
both the tumour and the adjacent non-affected pancreatic 
tissue which were then taken and stored separately. In 
addition, later pathological evaluations ascertained the origin 
from duodenal mucosa for all the PVAC samples.
Gene expression was profiled with Affymetrix 
GeneChip miRNA 2.0 Arrays and made available from 
ArrayExpress (E-MTAB-753). Symbols of miRNAs were 
converted to their most recent forms and annotated with their 
MIMAT IDs using the aliases tracking system provided by 
miRBase (Supplementary Information #Sheet B).
An external dataset (E-GEOD-60978), made 
of 52 PDAC and 6 normal tissues profiled by Agilent 
031181 Unrestricted Human miRNA V16.0 Microarray 
030840 platform, was used to crosscheck the evidences 
of expression correlation found in this work. No public 
datasets of miRNA expression profiles of PVAC were 
found, therefore a similar analysis for our PVAC 
counterpart could not be made.
Statistical analysis
In order to identify differentially expressed miRNAs 
between paired normal and PDAC/PVAC tumour tissues, 
paired t-tests were performed controlling for false discovery 
rate (fdr) allowing us to rank miRNAs according to their 
p-values. In each cohort, correlations between miRNAs 
expression were estimated using Spearman coefficient, in 
order to account for non-normal data distribution. These 
correlation matrices were then used for bioinformatics 
analyses. A p-value of 0.05 was considered for statistical 
significance. All analyses were performed using SAS 
Release 9.1 (SAS Institute, Cary, NC, USA).
Geometric and topological analysis
Similar to the analysis workflow followed in [85] 
and [86], we built undirected and weighted graphs of 
miRNA-to-miRNA based on correlation data. Nodes and 
edges of graphs represented miRNAs and their correlation 
values, if significant, respectively. Edges were not oriented 
since correlation is a symmetric measure, and were 
weighted with the Spearman coefficient. Initially, graphs 
were drawn separately for normal and tumour tissues. 
Then, only differentially expressed miRNAs between both 
tissues for both tumour entities were considered. Networks 
were drawn and analysed by Cytoscape 3.1.0 [87] and by 
a custom standalone tool written in C# and built over the 
library NodeXL 1.0.1.317.
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Global geometries
Graphs connectivity, reachability and cohesiveness 
were measured by well-known global topological indices. 
We first counted the number of connected components, 
which is the number of groups of nodes that are pairwise 
connected. A lower number of connected components 
suggest a stronger connectivity. Then, we measured the 
diameter, meant as the longest among all the shortest 
paths of a network, and the characteristic path length, also 
known as the average shortest path length, which gives 
the expected distance between two connected nodes. We 
further considered the network centralization, which is 1 
if a network resembles a star or 0 if it is decentralized, 
the average number of neighbours, which indicates the 
average connectivity of a node, and its normalized version: 
the network density. The density is a value between 0 
and 1. It shows how densely a network is populated 
with edges. A network that contains no edges and solely 
isolated nodes has a density of 0. In contrast, the density of 
a clique is 1 [88, 89]. Finally, we considered the network 
heterogeneity that reflects the tendency of a network to 
contain central and highly connected nodes, also known 
as hubs.
Local topological metrics
Critical miRNAs were recognized because of their 
topological measures: degree, betweenness, closeness 
and clustering coefficient [90-92]. All of them are based 
on the enumeration of links or shortest paths, whose 
length is calculated by summing the inverse weights of 
the traversing edges. The idea is that highly correlated 
miRNAs minimize the distance between nodes. Thus, 
while degree centrality relies on the fact that important 
nodes are those with the largest number of ties to other 
nodes, the betweenness index measures the influence 
a node has over the indirect correlation between even 
distant not-neighbour nodes. Closeness highlights nodes 
that are particularly ‘close’ to other nodes, or ‘reachable’ 
from other nodes. The shorter the geodesic distance from a 
node to other nodes, the higher its closeness centrality. On 
the contrary, the clustering coefficient measures the degree 
to which miRNAs tend to cluster together. Scatter plots 
summarizing the distributions of local topological indices 
are available in Supplementary Figure 1.
Cluster-based functional enrichment analysis
Important groups of miRNAs were identified by 
the Molecular Complex Detection (MCODE) clustering 
algorithm [93]. Weighting each miRNA by the local 
neighbourhood density and outward traversal from locally 
dense seed miRNAs, we isolated several dense regions 
that shared molecular targets and putatively cooperated to 
the fulfilment of a common biological process.
MirTarBase [94] and MirWalk [95] were queried 
(April 2015) to get experimentally validated target genes 
of selected miRNAs. Clashes of names and aliases 
were resolved by querying miRBase [96]. Target genes 
underwent functional enrichment analysis against the Gene 
Ontology FAT sub-set. Results obtained with DAVID [97] 
and ToppGene [98] web services were crosschecked with 
Babelomics [99] and considered if Bonferroni-corrected 
significance levels did not exceed 5%.
ACKNOWLEDGMENTS
None.
CONFLICTS OF INTEREST
Authors do not have any conflicts of interest to 
declare.
FUNDING
The study was supported by the Italian Ministry 
of Health grants (RC1603GA33, RC1703GA33) to the 
Division of Gastroenterology, IRCCS “Casa Sollievo della 
Sofferenza” Hospital, San Giovanni Rotondo (FG), Italy 
and by the “5x1000” voluntary contribution.
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA 
Cancer J Clin. 2016; 66:7-30.
2. Yabar CS, Winter JM. Pancreatic cancer: a review. 
Gastroenterol Clin North Am. 2016; 45:429-45.
3. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current 
status of molecular markers for early detection of 
sporadic pancreatic cancer. Biochim Biophys Acta. 2011; 
1815:44-64.
4. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, 
Buchler MW. Curative resection is the single most 
important factor determining outcome in patients with 
pancreatic adenocarcinoma. Br J Surg. 2004; 91:586-94.
5. Ahn DH, Bekaii-Saab T. Ampullary cancer: an overview. 
Am Soc Clin Oncol Educ Book. 2014.
6. Askew J, Connor S. Review of the investigation and surgical 
management of resectable ampullary adenocarcinoma. HPB 
(Oxford). 2013; 15:829-38.
7. Klein F, Jacob D, Bahra M, Pelzer U, Puhl G, Krannich 
A, Andreou A, Gül S, Guckelberger O. Prognostic 
factors for long-term survival in patients with ampullary 
carcinoma: the results of a 15-year observation period after 
pancreaticoduodenectomy. HPB Surg. 2014; 2014:970234.
8. Esquela-Kerscher A, Slack FJ. Oncomirs–microRNAs with 
a role in cancer. Nat Rev Cancer. 2006; 6:259-69.
9. Iorio MV, Croce CM. microRNA involvement in human 
cancer. Carcinogenesis. 2012; 33:1126-33.
10. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder 
H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM. 
Oncotarget105336www.impactjournals.com/oncotarget
MicroRNA expression patterns to differentiate pancreatic 
adenocarcinoma from normal pancreas and chronic 
pancreatitis. JAMA. 2007; 297:1901-8.
11. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel 
WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen 
TD. Expression profiling identifies microRNA signature in 
pancreatic cancer. Int J Cancer. 2007; 120:1046-54.
12. Mardin WA, Mees ST. MicroRNAs: novel diagnostic and 
therapeutic tools for pancreatic ductal adenocarcinoma? 
Ann Surg Oncol. 2009; 16:3183-9.
13. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, 
Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA. 
MicroRNA molecular profiles associated with diagnosis, 
clinicopathologic criteria, and overall survival in patients 
with resectable pancreatic ductal adenocarcinoma. Clin 
Cancer Res. 2012; 18:534-45.
14. van Dam S, Võsa U, van der Graaf A, Franke L, de 
Magalhães JP. Gene co-expression analysis for functional 
classification and gene–disease predictions. Brief 
Bioinform. 2017.
15. Seux M, Iovanna J, Dagorn JC, Dusetti NJ. MicroRNAs 
in pancreatic ductal adenocarcinoma: new diagnostic and 
therapeutic clues. Pancreatology. 2009; 9:66-72.
16. Steele CW, Oien KA, McKay CJ, Jamieson NB. 
Clinical potential of microRNAs in pancreatic ductal 
adenocarcinoma. Pancreas. 2011; 40:1165-71.
17. Diab M, Muqbil I, Mohammad RM, Azmi AS, Philip PA. 
The role of microRNAs in the diagnosis and treatment of 
pancreatic adenocarcinoma. J Clin Med. 2016; 5:59.
18. Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, 
Horn T, Wøjdemann M, Johansen JS. MicroRNA expression 
profiles associated with pancreatic adenocarcinoma and 
ampullary adenocarcinoma. Mod Pathol. 2012; 25:1609-22.
19. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs 
as oncogenes and tumor suppressors. Dev Biol. 2007; 
302:1-12.
20. Furukawa T, Sunamura M, Horii A. Molecular mechanisms 
of pancreatic carcinogenesis. Cancer Sci. 2006; 97:5.
21. Prenzel KL, Warnecke-Eberz U, Brabender J, Baldus SE, 
Bollschweiler E, Gutschow CA, Drebber U, Hoelscher 
AH, Schneider PM. Differential c-erbB-1 and c-erbB-2 
mRNA expression in cancer of the pancreas compared with 
cancer of the papilla of Vater. World J Gastroenterol. 2006; 
12:437-42.
22. Esposito I, Friess H, Büchler MW. Carcinogenesis of cancer 
of the papilla and ampulla: pathophysiological facts and 
molecular biological mechanisms. Langenbecks Arch Surg. 
2001; 386:163-71.
23. di Mola FF, di Sebastiano P. Pain and pain generation 
in pancreatic cancer. Langenbecks Arch Surg. 2008; 
393:919-22.
24. D’Haese JG, Hartel M, Demir IE, Hinz U, Bergmann F, 
Büchler MW, Friess H, Ceyhan GO. Pain sensation in 
pancreatic diseases is not uniform: the different facets of 
pancreatic pain. World J Gastroenterol. 2014; 20:9154-61.
25. Zhao Z, Zhao Q, Warrick J, Lockwood CM, Woodworth A, 
Moley KH, Gronowski AM. Circulating microRNA miR-
323-3p as a biomarker of ectopic pregnancy. Clin Chem. 
2012; 58:896-905.
26. Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS. 
Revisiting the ABCs of multidrug resistance in cancer 
chemotherapy. Curr Pharm Biotechnol. 2011; 12:570-94.
27. Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, 
Jiang L, Li J. Mammalian drug efflux transporters of the 
ATP binding cassette (ABC) family in multidrug resistance: 
a review of the past decade. Cancer Lett. 2016; 370:153-64.
28. Bai J, Sata N, Nagai H. Gene expression analysis for 
predicting gemcitabine sensitivity in pancreatic cancer 
patients. HPB (Oxford). 2007; 9:150-5.
29. Mohelnikova-Duchonova B, Brynychova V, Oliverius M, 
Honsova E, Kala Z, Muckova K, Soucek P. Differences in 
transcript levels of ABC transporters between pancreatic 
adenocarcinoma and nonneoplastic tissues. Pancreas. 2013; 
42:707-16.
30. Konig J, Hartel M, Nies AT, Martignoni ME, Guo J, Buchler 
MW, Friess H, Keppler D. Expression and localization 
of human multidrug resistance protein (ABCC) family 
members in pancreatic carcinoma. Int J Cancer. 2005; 
115:359-67.
31. Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM. 
ATP-binding cassette C transporters in human pancreatic 
carcinoma cell lines. Upregulation in 5-fluorouracil-
resistant cells. Pancreatology. 2009; 9:136-44.
32. Hagmann W, Jesnowski R, Lohr JM. Interdependence 
of gemcitabine treatment, transporter expression and 
resistance in human pancreatic carcinoma cells. Neoplasia. 
2010; 12:740-7.
33. Nambaru PK, Hübner T, Köck K, Mews S, Grube M, 
Payen L, Guitton J, Sendler M, Jedlitschky G, Rimmbach 
C, Rosskopf D, Kowalczyk DW, Kroemer HK, et al. Drug 
efflux transporter multidrug resistance-associated protein 
5 affects sensitivity of pancreatic cancer cell lines to the 
nucleoside anticancer drug 5-fluorouracil. Drug Metab 
Dispos. 2011; 39:132-9.
34. Radtke F, Raj K. The role of Notch in tumorigenesis: 
oncogene or tumour suppressor? Nat Rev Cancer. 2003; 
3:756-67.
35. Ma J, Xia J, Miele L, Sarkar FH, Wang Z. Notch signaling 
pathway in pancreatic cancer progression. Pancreat Disord 
Ther. 2013; 3:1000114.
36. Büchler P, Gazdhar A, Schubert M, Giese N, Reber HA, 
Hines OJ, Giese T, Ceyhan GO, Müller M, Büchler MW, 
Friess H. The Notch signaling pathway is related to 
neurovascular progression of pancreatic cancer. Ann Surg. 
2005; 242:791-800.
37. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, 
Iacobuzio-Donahue CA, Sriuranpong V, Iso T, Meszoely 
Oncotarget105337www.impactjournals.com/oncotarget
IM, Wolfe MS, Hruban RH, Ball DW, Schmid RM, 
Leach SD. Notch mediates TGF alpha-induced changes in 
epithelial differentiation during pancreatic tumorigenesis. 
Cancer Cell. 2003; 3:565-76.
38. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. 
Down-regulation of Notch-1 contributes to cell growth 
inhibition and apoptosis in pancreatic cancer cells. Mol 
Cancer Ther. 2006; 5:483-93.
39. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Inhibition 
of nuclear factor kappa b activity by genistein is mediated 
via Notch-1 signaling pathway in pancreatic cancer cells. 
Int J Cancer. 2006; 118:1930-6.
40. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira 
V, Hay N, Sarkar FH. Down-regulation of Notch-1 and 
Jagged-1 inhibits prostate cancer cell growth, migration 
and invasion, and induces apoptosis via inactivation of 
Akt, mTOR, and NF-kappaB signaling pathways. J Cell 
Biochem. 2010; 109:726-36.
41. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, 
Sharma SV, Gurumurthy S, Deshpande V, Kenific C, 
Settleman J, Majumder PK, Stanger BZ, Bardeesy N. 
Inhibition of gamma-secretase activity inhibits tumor 
progression in a mouse model of pancreatic ductal 
adenocarcinoma. Gastroenterology. 2009; 136:1741-9.
42. Zhang Y, Gan B, Liu D, Paik JH. FoxO family members in 
cancer. Cancer Biol Ther. 2011; 12:253-9.
43. Accili D, Arden KC. FoxOs at the crossroads of cellular 
metabolism, differentiation and transformation. Cell. 2004; 
117:421-6.
44. Martinez-Gac L, Marques M, Garcia Z, Campanero MR, 
Carrera AC. Control of cyclin G2 mRNA expression by 
forkhead transcription factors: novel mechanism for cell 
cycle control by phosphoinositide-3-kinase and forkhead. 
Mol Cell Biol. 2004; 24:2181-9.
45. Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, 
Motoyama N. FOXO forkhead transcription factors induce 
G(2)-M checkpoint in response to oxidative stress. J Biol 
Chem. 2002; 277:26729-32.
46. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, 
DiStefano PS, Chiang LW, Greenberg ME. DNA repair 
pathway stimulated by the forkhead transcript3ion factor 
FOXO3a through the Gadd45 protein. Science. 2002; 
296:530-4.
47. Tang TT, Dowbenko D, Jackson A, Toney L, Lewin DA, 
Dent AL, Lasky LA. The forkhead transcription factor 
AFX activates apoptosis by induction of the BCL-6 
transcriptional repressor. J Biol Chem. 2002; 277:14255-65.
48. Roy SK, Chen Q, Fu J, Shankar S, Srivastava RK. 
Resveratrol inhibits growth of orthotopic pancreatic tumors 
through activation of FOXO transcription factors. PLoS 
One. 2011; 6:e25166.
49. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser 
LM, Charles RP, Rabinovich BA, Hann B, Dankort D, 
Spellman PT, Phillips WA, Gray JW, et al. A central role for 
RAF→MEK→ERK signaling in the genesis of pancreatic 
ductal adenocarcinoma. Cancer Discov. 2012; 2:685-93.
50. Truty MJ, Urrutia R. Basics of TGF-beta and pancreatic 
cancer. Pancreatology. 2007; 7:423-35.
51. Singh P, Srinivasan R, Wig JD. The Smad family and its 
role in pancreatic cancer. Indian J Cancer. 2011; 48:351-60.
52. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, 
Sugiura Y, Tamai S, Matsubara O, Hatsuse K, Mochizuki 
H. The correlation between cytoplasmic overexpression of 
epidermal growth factor receptor and tumor aggressiveness: 
poor prognosis in patients with pancreatic ductal 
adenocarcinoma. Pancreas. 2004; 29:e1-8.
53. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, 
Lemoine NR. Expression of the Met/hepatocyte growth 
factor receptor in human pancreatic cancer. Cancer Res. 
1995; 55:1129-38.
54. Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, Yuan 
YZ. Positive expression of L1-CAM is associated with 
perineural invasion and poor outcome in pancreatic 
ductal adenocarcinoma. Ann Surg Oncol. 2010; 
17:2213-21.
55. Tsutsumi S, Morohashi S, Kudo Y, Akasaka H, Ogasawara 
H, Ono M, Takasugi K, Ishido K, Hakamada K, Kijima 
H. L1 Cell adhesion molecule (L1CAM) expression at 
the cancer invasive front is a novel prognostic marker of 
pancreatic ductal adenocarcinoma. J Surg Oncol. 2011; 
103:669-73.
56. Biankin AV, Waddell N, Kassahn KS, Gingras MC, 
Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch 
AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, et al. 
Pancreatic cancer genomes reveal aberrations in axon 
guidance pathway genes. Nature. 2012; 491:399-405.
57. Göhrig A, Detjen KM, Hilfenhaus G, Körner JL, Welzel 
M, Arsenic R, Schmuck R, Bahra M, Wu JY, Wiedenmann 
B, Fischer C. Axon guidance factor SLIT2 inhibits neural 
invasion and metastasis in pancreatic cancer. Cancer Res. 
2014; 74:1529-40.
58. Schopman NC, Heynen S, Haasnoot J, Berkhout B. A 
miRNA-tRNA mix-up: tRNA origin of proposed miRNA. 
RNA Biol. 2010; 7:573-6.
59. Birchenall-Roberts MC, Fu T, Bang OS, Dambach M, 
Resau JH, Sadowski CL, Bertolette DC, Lee HJ, Kim SJ, 
Ruscetti FW. Tuberous sclerosis complex 2 gene product 
interacts with human SMAD proteins. A molecular link 
of two tumor suppressor pathways. J Biol Chem. 2004; 
279:25605-13.
60. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. 
Oncogene. 2004; 23:4225-31.
61. Stroschein SL, Bonni S, Wrana JL, Luo K. Smad3 recruits 
the anaphase-promoting complex for ubiquitination and 
degradation of SnoN. Genes Dev. 2001; 15:2822-36.
62. Bengoechea-Alonso MT, Ericsson J. Tumor suppressor 
Fbxw7 regulates TGFβ signaling by targeting TGIF1 for 
degradation. Oncogene. 2010; 29:5322-8.
Oncotarget105338www.impactjournals.com/oncotarget
63. Pessah M, Prunier C, Marais J, Ferrand N, Mazars A, 
Lallemand F, Gauthier JM, Atfi A. c-Jun interacts with 
the corepressor TG-interacting factor (TGIF) to suppress 
Smad2 transcriptional activity. Proc Natl Acad Sci U S A. 
2001; 98:6198-203.
64. Wotton D, Massagué J. Smad transcriptional corepressors in 
TGF beta family signalling. Curr Top Microbiol Immunol. 
2001; 254:145-64.
65. Geng MM, Ellenrieder V, Wallrapp C, Muller-Pillasch F, 
Sommer G, Adler G, Gress TM. Use of representational 
difference analysis to study the effect of TGFB on the 
expression profile of a pancreatic cancer cell line. Genes 
Chromosomes Cancer. 1999; 26:70-9.
66. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how 
does cadherin dysfunction promote tumor progression? 
Oncogene. 2008; 27:6920-9.
67. Karayiannakis AJ, Syrigos KN, Polychronidis A, 
Simopoulos C. Expression patterns of alpha-, beta- and 
gamma-catenin in pancreatic cancer: correlation with 
E-cadherin expression, pathological features and prognosis. 
Anticancer Res. 2001; 21:4127-34.
68. Li YJ, Ji XR. Relationship between expression of 
E-cadherin-catenin complex and clinicopathologic 
characteristics of pancreatic cancer. World J Gastroenterol. 
2003; 9:368-72.
69. Joo YE, Rew JS, Park CS, Kim SJ. Expression of 
E-cadherin, alpha- and beta-catenins in patients with 
pancreatic adenocarcinoma. Pancreatology. 2002; 2:129-37.
70. Chen HC, Chu RY, Hsu PN, Hsu PI, Lu JY, Lai KH, 
Tseng HH, Chou NH, Huang MS, Tseng CJ, Hsiao M. 
Loss of E-cadherin expression correlates with poor 
differentiation and invasion into adjacent organs in gastric 
adenocarcinomas. Cancer Lett. 2003; 201:97-106.
71. Winter JM, Ting AH, Vilardell F, Gallmeier E, Baylin SB, 
Hruban RH, Kern SE, Iacobuzio-Donahue CA. Absence 
of E-cadherin expression distinguishes noncohesive 
from cohesive pancreatic cancer. Clin Cancer Res. 2008; 
14:412-8.
72. Petkov PM, Graber JH, Churchill GA, DiPetrillo K, 
King BL, Paigen K. Evidence of a large-scale functional 
organization of Mammalian chromosomes. PLoS Biol. 
2007; 5:e127.
73. Yang Y, Han L, Yuan Y, Li J, Hei N, Liang H. Gene 
co-expression network analysis reveals common system-
level properties of prognostic genes across cancer types. 
Nat Commun. 2014; 5:3231.
74. Nepusz T, Yu H, Paccanaro A. Detecting overlapping 
protein complexes in protein-protein interaction networks. 
Nat Meth. 2012; 9:471-2.
75. Sahasrabuddhe NA, Huang TC, Kumar P, Yang Y, Ghosh B, 
Leach SD, Chaerkady R, Pandey A. Ablation of Dicer leads 
to widespread perturbation of signaling pathways. Biochem 
Biophys Res Commun. 2015; 463:389-94.
76. Morris JP 4th, Greer R, Russ HA, von Figura G, Kim GE, 
Busch A, Lee J, Hertel KJ, Kim S, McManus M, Hebrok M. 
Dicer regulates differentiation and viability during mouse 
pancreatic cancer initiation. PLoS One. 2014; 9:e95486.
77. Wang YJ, McAllister F, Bailey JM, Scott SG, Hendley AM, 
Leach SD, Ghosh B. Dicer is required for maintenance of 
adult pancreatic acinar cell identity and plays a role in Kras-
driven pancreatic neoplasia. PLoS One. 2014; 9:e113127.
78. Riley T, Sontag E, Chen P, Levine A. Transcriptional 
control of human p53-regulated genes. Nat Rev Mol Cell 
Biol. 2008; 9:402-12.
79. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. 
Nature. 2000; 408:307-10.
80. Yu H, Liu Z, Huang YJ, Yin M, Wang LE, Wei Q. 
Association between single nucleotide polymorphisms in 
ERCC4 and risk of squamous cell carcinoma of the head 
and neck. PLoS One. 2012; 7:e41853.
81. Hasan S, Hassa PO, Imhof R, Hottiger MO. Transcription 
coactivator p300 binds PCNA and may have a role in DNA 
repair synthesis. Nature. 2001; 410:387-91.
82. Zhang Y, Morris JP 4th, Yan W, Schofield HK, Gurney 
A, Simeone DM, Millar SE, Hoey T, Hebrok M, Pasca 
di Magliano M. Canonical wnt signaling is required for 
pancreatic carcinogenesis. Cancer Res. 2013; 73:4909-22.
83. Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz 
AA, Hebrok M. Hedgehog/Ras interactions regulate early 
stages of pancreatic cancer. Genes Dev. 2006; 20:3161-73.
84. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, 
Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del 
Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw 
AL, Hebrok M. Hedgehogs is an early and late mediator of 
pancreatic cancer tumorigenesis. Nature. 2003; 425:851-6.
85. Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, 
Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia 
G, Gentile A, Mastrodonato N, Carella M, et al. MiRNA 
expression profiles identify drivers in colorectal and 
pancreatic cancers. PLoS One. 2012; 7:e33663.
86. Mazzoccoli G, Tomanin R, Mazza T, D’Avanzo F, Salvalaio 
M, Rigon L, Zanetti A, Pazienza V, Francavilla M, Giuliani 
F, Vinciguerra M, Scarpa M. Circadian transcriptome 
analysis in human fibroblasts from Hunter syndrome and 
impact of iduronate-2-sulfatase treatment. BMC Med 
Genomics. 2013; 6:37.
87. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, 
Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a 
software environment for integrated models of biomolecular 
interaction networks. Genome Res. 2003; 13:2498-504.
88. Mazza T, Romanel A, Jordán F. Estimating the divisibility 
of complex biological networks by sparseness indices. Brief 
Bioinform. 2010; 11:364-74.
89. Menniti S, Castagna E, Mazza T. Estimating the global 
density of graphs by a sparseness index. Appl Math 
Comput. 2013; 224:346-57.
Oncotarget105339www.impactjournals.com/oncotarget
90. Barabasi AL. Network science. Philos Trans A Math Phys 
Eng Sci. 2013; 371:20120375.
91. Sabidussi G. The centrality index of a graph. Psychometrika. 
1966; 31:581-603.
92. Mazza T, Prandi D. Stability analysis of biological network 
topologies during stochastic simulation. SIMUTools 2011 
Proceedings of the 4th International ICST Conference on 
Simulation Tools and Techniques, 51-6.
93. Bader GD, Hogue CW. An automated method for finding 
molecular complexes in large protein interaction networks. 
BMC Bioinformatics. 2003; 4:2.
94. Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou 
CH, Chu CF, Huang HY, Lin CM, Ho SY, Jian TY, Lin FM, 
Chang TH, et al. miRTarBase update 2014: an information 
resource for experimentally validated miRNA-target 
interactions. Nucleic Acids Res. 2014; 42:D78-85.
95. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: 
prediction of possible miRNA binding sites by “walking” 
the genes of three genomes. J Biomed Inform. 2011; 
44:839-47.
96. Kozomara A, Griffiths-Jones S. miRBase: integrating 
microRNA annotation and deep-sequencing data. Nucleic 
Acids Res. 2011; 39:D152-7.
97. Huang DW, Sherman BT, Lempicki RA. Systematic 
and integrative analysis of large gene lists using DAVID 
bioinformatics resources. Nature Protoc. 2009; 4:44-57.
98. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene 
Suite for gene list enrichment analysis and candidate gene 
prioritization. Nucleic Acids Res. 2009; 37:W305-11.
99. Medina I, Carbonell J, Pulido L, Madeira SC, Goetz 
S, Conesa A, Tárraga J, Pascual-Montano A, Nogales-
Cadenas R, Santoyo J, García F, Marbà M, Montaner D, 
et al. Babelomics: an integrative platform for the analysis 
of transcriptomics, proteomics and genomic data with 
advanced functional profiling. Nucleic Acids Res. 2010; 
38:W210-3.
